Patient demographics and disease characteristics.
| TARGET Study16 | MONARCH Study17 | ||||
|---|---|---|---|---|---|
| Characteristics | Placebo + csDMARD, n = 181 | Sarilumab SC 150 mg q2w + csDMARD, n = 181 | Sarilumab SC 200 mg q2w + csDMARD, n = 184 | Adalimumab SC 40 mg q2w/qw, n = 185 | Sarilumab SC 200 mg q2w, n = 184 |
| Age, yrs, mean ± SD | 51.9 ± 12.4 | 54.0 ± 11.7 | 52.9 ± 12.9 | 53.6 ± 11.9 | 50.9 ± 12.6 |
| Female, n (%) | 154 (85.1) | 142 (78.5) | 151 (82.1) | 150 (81.1) | 157 (85.3) |
| White, n (%) | 124 (68.5) | 134 (74.0) | 130 (70.7) | 164 (88.6) | 171 (92.9) |
| Duration of RA, yrs, mean ± SD | 12.0 ± 10.0 | 11.6 ± 8.6 | 12.7 ± 9.6 | 6.6 ± 7.8 | 8.1 ± 8.1 |
| Backgrounda or priorb csDMARD, n (%) | |||||
| Methotrexate | 158 (87.3) | 154 (85.1) | 156 (84.8) | 185 (100) | 184 (100) |
| Leflunomide | 17 (9.4) | 17 (9.4) | 18 (9.8) | 45 (24.3) | 42 (22.8) |
| Sulfasalazine | 5 (2.8) | 12 (6.6) | 15 (8.2) | 44 (23.8) | 59 (32.1) |
| Hydroxychloroquine | 10 (5.5) | 14 (7.7) | 13 (7.1) | 43 (23.2) | 41 (22.3) |
| Baseline DAS28-CRP, mean ± SD | 6.2 ± 0.9 | 6.1 ± 0.9 | 6.3 ± 1.0 | 6.0 ± 0.9 | 6.0 ± 0.9 |
| Baseline RAID scores, mean ± SD | |||||
| Total score | 6.6 ± 2.0 | 6.5 ± 2.0 | 6.8 ± 1.8 | 6.4 ± 2.0 | 6.7 ± 1.7 |
| Pain | 7.3 ± 1.9 | 7.2 ± 2.0 | 7.5 ± 1.8 | 6.9 ± 2.1 | 7.2 ± 1.9 |
| Functional impairment | 7.0 ± 2.1 | 6.9 ± 2.0 | 7.2 ± 1.9 | 6.7 ± 2.2 | 6.9 ± 2.1 |
| Fatigue | 6.6 ± 2.5 | 6.6 ± 2.5 | 6.9 ± 2.3 | 6.4 ± 2.4 | 6.7 ± 2.1 |
| Sleep difficulties | 6.4 ± 2.9 | 5.8 ± 2.9 | 6.1 ± 2.8 | 5.9 ± 2.8 | 6.1 ± 2.7 |
| Physical well-being | 6.8 ± 2.1 | 6.5 ± 2.2 | 6.8 ± 2.2 | 6.5 ± 2.3 | 6.9 ± 2.0 |
| Emotional well-being | 5.9 ± 2.7 | 6.0 ± 2.6 | 6.1 ± 2.5 | 6.0 ± 2.6 | 6.4 ± 2.4 |
| Coping | 5.7 ± 2.6 | 5.8 ± 2.5 | 6.2 ± 2.5 | 5.8 ± 2.6 | 6.1 ± 2.3 |
↵a Background csDMARD used in TARGET; concomitant use of 2 or 3 csDMARD was reported by 6.4% and 0.7% of patients, respectively.
↵b Prior csDMARD other than methotrexate used in MONARCH: named csDMARD were included if used in > 5% of the population. DAS28-CRP: 28-joint Disease Activity Score using C-reactive protein; csDMARD: conventional synthetic disease-modifying antirheumatic drug; qw: once weekly; q2w: every 2 weeks; RA: rheumatoid arthritis; SC: subcutaneous; RAID: RA Impact of Disease scale.